Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCATCo Regulatory News (CAT)

  • This share is currently suspended. It was suspended at a price of 37.50
  • There is currently no data for CAT

Dividend Declaration and Update C Share Conversion

29 Jan 2016 07:00

RNS Number : 3765N
CATCo Reinsurance Opps Fund Ltd
29 January 2016
 

 

 

 

CATCo Reinsurance Opportunities Fund Ltd. ("the Company")

 

Declaration of Annual Dividend and Update on C Share Conversion

 

 

To: SFM, London Stock Exchange and Bermuda Stock Exchange

Date: 29 January 2016

 

At the launch of the Company, the Board of Directors indicated the intention to pay an annual dividend in respect of any Fiscal Year of an amount equal to LIBOR plus 5 per cent of the Net Asset Value as at the end of the relevant Fiscal Year.*

 

The Board of Directors are declaring an annual dividend of $0.06619 in respect of the Ordinary Shares for the year to 31 December 2015. The record date for this dividend will be 12 February 2016 and therefore the Ordinary Shares will go ex-dividend on 11 February 2016. It is expected that this final dividend will be paid to shareholders on 26 February 2016.

 

In view of the Side Pockets recently established by the Company's Investment Manager following the UK floods and US tornado events, the Board has decided that the conversion of the C Shares to Ordinary Shares will not now occur until all of these Side Pockets have either been released or deemed immaterial, in order to protect the new capital from exposure to legacy losses.

 

The Company's Investment Manager anticipates that a significant proportion of these Side Pockets will be released during 2016, as the losses are expected to stabilise relatively quickly. The Board will provide a further update to Shareholders regarding the timing of the conversion of the C Shares to Ordinary Shares in due course.

 

* This is a target only and not a profit forecast. There can be no assurance that the Company will make distributions in any Fiscal Year.

 

-End-

 

For further information:

Judith Wynne,

Company Secretary and General Counsel

Markel CATCo Investment Management Ltd

Telephone: +1 441 493 9005

Email: judith.wynne@markelcatco.com

 

Mark Way

Fund Operations and Investor Relations Director

Markel CATCo Investment Management Ltd

Telephone: +1 441 493 9003

Email: mark.way@markelcatco.com

 

David Benda / Hugh Jonathan

Numis Securities Limited

Telephone: +44 (0) 20 7260 1000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DIVBPMLTMBJTBIF
Date   Source Headline
13th Jun 20064:50 pmRNSRule 8.3- Cambridge Antibody
13th Jun 20063:54 pmRNSRule 2.10 Announcement
13th Jun 200612:18 pmRNSEPT Disclosure
13th Jun 200611:42 amRNSEPT Disclosure
13th Jun 200611:35 amRNSEPT Disclosure
13th Jun 200610:20 amRNSEPT Disclosure
12th Jun 20065:35 pmRNSRule 8.3 - Cambridge Antibody
12th Jun 200612:00 pmRNSEPT Disclosure
12th Jun 200611:34 amRNSEPT Disclosure
12th Jun 200611:14 amRNSRule 8.3- (CAT)
12th Jun 200610:08 amRNSEPT Disclosure
12th Jun 20067:00 amRNSRule 8.3- Cambridge Antibody
9th Jun 20061:30 pmRNSRule 8.3- (CAT)
9th Jun 200612:36 pmRNSEPT Disclosure
9th Jun 200611:56 amRNSEPT Disclosure
9th Jun 200611:54 amRNSEPT Disclosure
9th Jun 200611:38 amRNSRule 8.3-Cambridge Antibody
8th Jun 20064:19 pmRNSRule 2.10 Announcement
8th Jun 20062:21 pmRNSEPT Disclosure
8th Jun 20061:14 pmRNSRule 8.3- (CAT)
8th Jun 200610:49 amRNSEPT Disclosure
7th Jun 20065:01 pmRNSHolding(s) in Company
7th Jun 20064:55 pmRNSRule 8.3- Cambridge Anti Tech
7th Jun 200612:38 pmRNSRule 8.3- (CAT)
7th Jun 200612:08 pmRNSEPT Disclosure
7th Jun 200610:00 amRNSOffer for Cambridge Antibody
6th Jun 20064:01 pmRNSRule 8.3- Cambridge Antibody
6th Jun 20063:45 pmRNSRule 8.3- Cambridge Antibody
6th Jun 200612:43 pmRNSEPT Disclosure
5th Jun 20066:00 pmRNSEPT Disclosure
5th Jun 20061:10 pmRNSRule 8.3- (CAT)
5th Jun 200612:55 pmRNSEPT Disclosure
5th Jun 200611:24 amRNSEPT Disclosure
2nd Jun 20062:14 pmRNSEPT Disclosure
2nd Jun 20061:19 pmRNSRule 8.3- (CAT)
2nd Jun 200612:27 pmRNSEPT Disclosure
2nd Jun 200612:22 pmRNSEPT Disclosure
2nd Jun 20067:00 amRNSRule 8.3- Cambridge Antibody
1st Jun 20064:22 pmRNSRule 8.3- Cambridge Antibody
1st Jun 20063:21 pmRNSHolding(s) in Company
1st Jun 200612:25 pmRNSEPT Disclosure
1st Jun 200611:10 amRNSEPT Disclosure
31st May 20063:13 pmRNSRule 8.3- (CAT)
31st May 20063:00 pmRNSMerger Update
31st May 20061:04 pmRNSRule 8.3- Cambridge Antibody
31st May 200611:43 amRNSEPT Disclosure
31st May 200611:27 amRNSEPT Disclosure
31st May 200611:25 amRNSEPT Disclosure
30th May 20063:25 pmRNSRule 8.3- (CAT)
30th May 20063:16 pmRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.